LUPINLupin Ltd.

₹1953-0.32%

Market Cap

₹89,510.84 Cr

Stock P/E

24.20

ROCE

21.97%

ROE

21.13%

Book Value

₹401.55

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
U.S. growth momentum with Tolvaptan; robust pipeline and high focus on complex products.
•
Strong start to the fiscal year with double-digit growth and margin expansion.

NEGATIVES

•
LOE on in-licensed diabetes brands weighed on growth rates.
•
FY26 margins expected to be tempered by higher R&D and lower PLI; full-year EBITDA guidance unchanged but tempered.

Peers Summary

Sector Leader

Lupin Ltd. stands out among its peers with strong growth metrics, solid profitability, and attractive valuation ratios. The company shows a robust revenue growth of over 20% YoY, a high ROE of over 21%, and a low debt-equity ratio, positioning it as a leader in the pharmaceuticals sector. In comparison, some peers appear overvalued while others show signs of financial stress.

Key Points

• Lupin Ltd. has the highest revenue growth (YoY) at 20.24%.
• Dr. Reddy's Laboratories leads in profitability metrics with the highest ROE (21.76%) and ROCE (26.86%).
• Cipla Ltd. offers attractive valuation with a PE ratio of 23.73, while Sun Pharmaceutical appears overvalued with a PE of 87.59.
• Divi's Laboratories Ltd. displays high profit margins but struggles with revenue growth, making it a financially weak pick.

Top Performers

Lupin Ltd.

Highest revenue growth YoY at 20.24% and solid EPS growth of 71.84.

Dr. Reddy's Laboratories Ltd.

Leads in ROE (21.76%) and ROCE (26.86%), indicating strong profitability.

Cipla Ltd.

Offers attractive valuation metrics with a PE of 23.73 and solid growth.

Explore

Watchlists

Command Palette